Medical Faculty, RWTH Aachen University, Aachen, Germany.
Department of Anaesthesiology, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Crit Care. 2024 Nov 7;28(1):359. doi: 10.1186/s13054-024-05128-2.
Evidence on the benefits of fiber-supplemented enteral nutrition (EN) in critically ill patients is inconsistent, and critical care nutrition guidelines lack recommendations based on high-quality evidence. This systematic review and meta-analysis (SRMA) aims to provide a current synthesis of the literature on this topic.
For this SRMA of randomized controlled trials (RCT), electronic databases (MEDLINE, EMBASE, CENTRAL) were searched systematically from inception to January 2024 and updated in June 2024. Trials investigating clinical effects of fiber-supplemented EN versus placebo or usual care in adult critically ill patients were selected. Two independent reviewers extracted data and assessed the risk of bias of the included studies. Random-effect meta-analysis and trial sequential analysis (TSA) were conducted. The primary outcome was overall mortality, and one of the secondary outcomes was diarrhea incidence. Subgroup analyses were also performed for both outcomes.
Twenty studies with 1405 critically ill patients were included. In conventional meta-analysis, fiber-supplemented EN was associated with a significant reduction of overall mortality (RR 0.66, 95% CI 0.47, 0.92, p = 0.01, I = 0%; 12 studies) and diarrhea incidence (RR 0.70, 95% CI 0.51, 0.96, p = 0.03, I = 51%; 11 studies). However, both outcomes were assessed to have very serious risk of bias, and, according to TSA, a type-1 error cannot be ruled out. No subgroup differences were found for the primary outcome.
Very low-certainty evidence suggests that fiber-supplemented EN has clinical benefits. High-quality multicenter RCTs with large sample sizes are needed to substantiate any firm recommendation for its routine use in this group of patients. PROSPERO registration number: CRD42023492829.
关于纤维补充型肠内营养(EN)在危重症患者中的益处的证据并不一致,且重症监护营养指南缺乏基于高质量证据的推荐。本系统评价和荟萃分析(SRMA)旨在对该主题的文献进行当前综合分析。
对于这项 SRMA 中的随机对照试验(RCT),从创建到 2024 年 1 月系统地检索了电子数据库(MEDLINE、EMBASE、CENTRAL),并于 2024 年 6 月进行了更新。选择了调查纤维补充型 EN 与安慰剂或常规治疗相比在成年危重症患者中的临床效果的试验。两名独立审查员提取数据并评估纳入研究的偏倚风险。进行了随机效应荟萃分析和试验序贯分析(TSA)。主要结局是总体死亡率,次要结局之一是腹泻发生率。还对这两个结局进行了亚组分析。
共纳入 20 项研究,涉及 1405 名危重症患者。在常规荟萃分析中,纤维补充型 EN 与总体死亡率显著降低相关(RR 0.66,95%CI 0.47,0.92,p=0.01,I=0%;12 项研究)和腹泻发生率降低相关(RR 0.70,95%CI 0.51,0.96,p=0.03,I=51%;11 项研究)。然而,这两个结局都被评估为存在非常严重的偏倚风险,并且根据 TSA,不能排除一类错误。主要结局未发现亚组差异。
极低确定性证据表明,纤维补充型 EN 具有临床益处。需要高质量的多中心 RCT 来证实其在该患者群体中常规使用的任何确定性推荐。PROSPERO 注册号:CRD42023492829。